<unk>  is indicated for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
Sotorasib
Belinostat
Tezacaftor
Alpelisib
Umbralisib
Corbevax
Zantac
Snoezelen